Research Partnerships

GNA Biosolutions is proud of our network of renowned partners, who collaborate with us to jointly create solutions that enable faster and more targeted diagnostics, and cost-effective patient management. Below, we list some important contributions in funded research projects. To find out more about research partnerships with GNA Biosolutions, please contact

 

Hospital admission testing of resistant pathogens using Laser PCR (Acronym: KAREL)
Problem: Methicillin-resistant Staphylococcus aureus (MRSA) bacteria are resistant to many antibiotics and can cause a variety of problems ranging from skin infections and sepsis, to pneumonia and bloodstream infections.
Solution: A Laser PCR platform and MRSA detection assay for the Point of Care that provides healthcare professionals with ultrafast testing of patients entering the hospital system, in order to reduce unnecessary patient isolation and prevent proliferation of infection within the hospital environment.
This project is co-funded by the German Federal Ministry of Education and Research (BMBF).

 

Rapid test for antibiotic-resistant Gram-negative pathogens (Acronym: SAGE)
Problem: Gram-negative bacteria are increasingly resistant to most available antibiotics.
Solution: An ultrafast sample to result platform with highly multiplexed assays to provide specific and rapid detection of resistance in multi-drug resistant Gram-negative bachteria (MDRGN), to allow rapid monitoring of infections, as well as investigation and containment of outbreaks.
This project is co-funded by the German Federal Ministry of Education and Research (BMBF).

 

Ultra-Fast Molecular Filovirus Diagnostics (Acronym: FILODIAG)
Problem: Patients with early symptoms often need to be contained with non-Ebola patients, until diagnostic results are in.
Solution: Real-Time Laser PCR and RNA-based assays to detect Ebola with a robust system, operatable at resource-limited settings.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115844. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.